{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04803006",
            "orgStudyIdInfo": {
                "id": "TCD601A201"
            },
            "organization": {
                "fullName": "ITB-Med LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of TCD601 in the Induction of Tolerance in de Novo Renal Transplantation (PANORAMA)",
            "officialTitle": "An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, for Tolerance Induction in de Novo Living Donor Renal Transplantation",
            "therapeuticArea": [
                "Nephrology and Renal Diseases"
            ],
            "study": "a-study-of-in-the-induction-of-tolerance-in-de-novo-renal-transplantation-panorama"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-03-14",
            "studyFirstSubmitQcDate": "2021-03-14",
            "studyFirstPostDateStruct": {
                "date": "2021-03-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ITB-Med LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in de novo living donor renal transplantation"
        },
        "conditionsModule": {
            "conditions": [
                "Kidney Transplantation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1",
                    "type": "EXPERIMENTAL",
                    "description": "TCD601administered with non-myeloablative conditioning and standard of care immunosuppression",
                    "interventionNames": [
                        "Biological: TCD601"
                    ]
                },
                {
                    "label": "Arm 2",
                    "type": "EXPERIMENTAL",
                    "description": "TCD601administered with non-myeloablative conditioning and standard of care immunosuppression",
                    "interventionNames": [
                        "Biological: TCD601"
                    ]
                },
                {
                    "label": "Arm 3",
                    "type": "EXPERIMENTAL",
                    "description": "TCD601administered with non-myeloablative conditioning and standard of care immunosuppression",
                    "interventionNames": [
                        "Biological: TCD601"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "TCD601",
                    "description": "Investigational Product",
                    "armGroupLabels": [
                        "Arm 1",
                        "Arm 2",
                        "Arm 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "The optimal regimen for renal allograft tolerance while minimizing chimeric transition syndrome",
                    "description": "The proportion of patients off immunosuppression with good safety and tolerability",
                    "timeFrame": "24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "The incidence of biopsy proven acute rejection, death and graft loss",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "The incidence of de novo donor-specific antibody",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Able to understand the study requirements and provide written informed consent before any study assessment is performed\n* Male or female patients \u2265 18 to 65 years of age\n* Recipient of a first renal transplant from a non-HLA identical, but at least haploidentical, ABO compatible living donor\n\nKey Exclusion Criteria:\n\n* Women of child-bearing potential, unless willing to comply with the use of highly effective methods of contraception as defined by the protocol\n* A history of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix\n* Recipient with anti-HLA donor-specific antibody (DSA)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Shannon Zentmeyer, BSN",
                    "role": "CONTACT",
                    "phone": "347-326-1985",
                    "email": "shannon.zentmeyer@itb-med.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Nick Hryciw, MA",
                    "affiliation": "ITB-MED",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCSF Connie Frank Transplant Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "University of Maryland",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Cooperman Barnabas Medical Center",
                    "status": "RECRUITING",
                    "city": "Livingston",
                    "state": "New Jersey",
                    "zip": "07039",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.79593,
                        "lon": -74.31487
                    }
                },
                {
                    "facility": "NYU Langone",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Columbia University Irving Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}